Why join the SEMA team?

Headline for 1 column

Innovative financing tools, such as pooled funding, demand aggregation, advance purchase agreements, volume guarantees, and leveraging balance sheets will be critical to rapid procurement and deployment of coronavirus medical products. A crisis of this scale requires creative thinking. In the same way that scientists and politicians have ditched business as usual to respond to the pandemic, financing institutions should do the same. We need to be willing to do ‘whatever it takes’.

Headline for 1 column

Innovative financing tools, such as pooled funding, demand aggregation, advance purchase agreements, volume guarantees, and leveraging balance sheets will be critical to rapid procurement and deployment of coronavirus medical products. A crisis of this scale requires creative thinking. In the same way that scientists and politicians have ditched business as usual to respond to the pandemic, financing institutions should do the same. We need to be willing to do ‘whatever it takes’.

Headline for 1 column

Innovative financing tools, such as pooled funding, demand aggregation, advance purchase agreements, volume guarantees, and leveraging balance sheets will be critical to rapid procurement and deployment of coronavirus medical products. A crisis of this scale requires creative thinking. In the same way that scientists and politicians have ditched business as usual to respond to the pandemic, financing institutions should do the same. We need to be willing to do ‘whatever it takes’.

Headline for 1 column

Innovative financing tools, such as pooled funding, demand aggregation, advance purchase agreements, volume guarantees, and leveraging balance sheets will be critical to rapid procurement and deployment of coronavirus medical products. A crisis of this scale requires creative thinking. In the same way that scientists and politicians have ditched business as usual to respond to the pandemic, financing institutions should do the same. We need to be willing to do ‘whatever it takes’.

Innovative financing tools, such as pooled funding, demand aggregation, advance purchase agreements, volume guarantees, and leveraging balance sheets will be critical to rapid procurement and deployment of coronavirus medical products. A crisis of this scale requires creative thinking. In the same way that scientists and politicians have ditched business as usual to respond to the pandemic, financing institutions should do the same. We need to be willing to do ‘whatever it takes’.